

Defining Value and Quality in Cancer Care: Implications for the Practicing General Oncologist

CME Information

TARGET AUDIENCE

This activity is intended for medical oncologists.

OVERVIEW OF ACTIVITY

Healthcare delivery and its related costs represent the largest and fastest-growing sector of the United States economy. However, this significant investment has not translated into longer life expectancies for US citizens. Most policy makers and governing bodies agree that this situation is unsustainable and, more importantly, irresponsible, given the lack of correlation between expenditures and outcomes for the public at large. Perhaps equally important, recent shifts in how institutions and healthcare professionals are or will be compensated have generated uncertainty and questions among practicing clinicians. As such, additional resources are clearly necessary to assist medical oncologists and other allied cancer professionals in not only better understanding why significant changes are needed but also describing how specific initiatives, programs and models will potentially achieve these important goals. This CME program uses a roundtable discussion with a diverse group of leaders in this field to empower clinicians to continue dialoguing about the relevance of quality and value, provide them with important information and give them confidence that their participation can make a difference in the care delivered at the institutional and patient levels.

LEARNING OBJECTIVES

- Develop a better understanding of evolving quality-centered healthcare delivery systems, with a particular emphasis on defining, assessing and achieving performance measures specific to the care of patients with cancer.
- Review examples of alternative and/or investigational cancer delivery models (eg, oncology medical homes, cancer pathways, et cetera) that attempt to improve the quality, efficiency and affordability of care for patients with cancer.
- Identify opportunities for medical oncologists to improve the coordination of care for patients with cancer within their institution or local healthcare system.
- Define opportunities for the medical oncologist and his/her support staff to foster shared decision-making and heighten

the engagement and satisfaction of patients and family members in their cancer care journey.

- Outline learning platforms being instituted by governing bodies to provide practicing oncologists with continuous feedback regarding the comparable effectiveness and quality of care being delivered in their own practices.
- Summarize the effects of rising healthcare costs or volume-based models on oncology practices.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/QualityTT115/Video/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Patricia A Ganz, MD

Distinguished Professor
Health Policy & Management and Medicine
UCLA Fielding School of Public Health
David Geffen School of Medicine at UCLA
Director, Cancer Prevention and Control Research
Jonsson Comprehensive Cancer Center
Los Angeles, California

No relevant conflicts of interest to disclose.

Lowell L Hart, MD

Scientific Director of Clinical Research
Director, Drug Development Program
Florida Cancer Specialists
Fort Myers, Florida

Contracted Research: Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation; **Speakers Bureau:** Genentech BioOncology, Novartis Pharmaceuticals Corporation.

Bruce E Hillner, MD

Professor of Medicine
Department of Internal Medicine
Member, Massey Cancer Center
Virginia Commonwealth University
Richmond, Virginia

Consulting Agreement: Bristol-Myers Squibb Company.

Michael Kolodziej, MD

National Medical Director
Oncology Solutions
Aetna
Singerlands, New York

No relevant conflicts of interest to disclose.

Lowell E Schnipper, MD

Theodore and Evelyn Berenson Professor of Medicine
Harvard Medical School
Clinical Director, Cancer Center
Chief, Hematology/Oncology Division
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Advisory Committee: eviti Inc; **Consulting Agreement:** Merck;
Editor-in-Chief: UpToDate.

John D Spradio, MD

Lead Physician
Consultants in Medical Oncology and Hematology PC
President, Oncology Management Services Inc
Drexel Hill, Pennsylvania

Contracted Research and Speakers Bureau: Genentech BioOncology.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL

REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Astellas Pharma Global Development Inc/Medivation Inc, Celgene Corporation, Genentech BioOncology, Lilly and Teva Oncology.

Hardware/Software Requirements:

A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: January 2016

Expiration date: January 2017

Select Publications

- American Society of Clinical Oncology. **The state of cancer care in America, 2015: A report by the American Society of Clinical Oncology.** *J Oncol Pract* 2015;11(2):79-113.
- American Society of Clinical Oncology. **Potential approaches to sustainable, long-lasting payment reform in oncology.** *J Oncol Pract* 2014;10(4):254-8.
- Bakitas M. **The ENABLE III randomized controlled trial of concurrent palliative oncology care.** *Proc ASCO* 2014;Abstract 9512.
- Barr TR, Towle EL. **Oncology practice trends from the National Practice Benchmark.** *J Oncol Pract* 2014;11(1):407-10.
- Cox JV et al. **Understanding and surviving the transition to value-based oncology.** *Am Soc Clin Oncol Educ Book* 2013.
- Dionne-Odom JN. **Benefits of immediate versus delayed palliative care to informal family caregivers of persons with advanced cancer: Outcomes from the ENABLE III randomized clinical trial.** *Proc ASCO* 2014;Abstract LBA9513.
- Downs CG et al. **The Affordable Care Act: Where are we now? An NCCN roundtable.** *J Natl Compr Canc Netw* 2014;12(5 Suppl):745-7.
- Ganz PA. **Institute of Medicine report on delivery of high-quality cancer care.** *J Oncol Pract* 2014;10(3):193-5.
- Gawande A. **Big med: Restaurant chains have managed to combine quality control, cost control, and innovation. Can health care?** Available at: <http://www.newyorker.com/magazine/2012/08/13/big-med>
- Kolodziej M et al. **Cancer care and accountable care organizations: The unknown patient experience landscape.** *Oncology (Williston Park)* 2013;27(10):953, 958-9.
- Nekhlyudov L et al. **Patient-centered, evidence-based, and cost-conscious cancer care across the continuum: Translating the Institute of Medicine report into clinical practice.** *CA Cancer J Clin* 2014;64(6):408-21.
- Neuss MN et al. **Measuring the improving quality of outpatient care in medical oncology practices in the United States.** *J Clin Oncol* 2013;31(11):1471-7.
- Newcomer LN et al. **Changing physician incentives for affordable, quality cancer care: Results of an episode payment model.** *J Oncol Pract* 2014;10(5):322-6.
- Partridge AH et al. **Developing a service model that integrates palliative care throughout cancer care: The time is now.** *J Clin Oncol* 2014;32(29):3330-6.
- Porter M et al. **What is value in health care?** *N Engl J Med* 2010;363(26):2477-81.
- Schilsky RL et al. **Building a rapid learning health care system for oncology: The regulatory framework of CancerLinQ.** *J Clin Oncol* 2014;32(22):2373-9.
- Schnipper LE. **Quality oncology practice initiative: An approach to solving the value equation.** *J Oncol Pract* 2014;10(3):219-20.
- Schnipper LE et al. **American Society of Clinical Oncology 2013 top five list in oncology.** *J Clin Oncol* 2013;31(34):4362-70.
- Schnipper LE, Meropol NJ. **Payment for cancer care: Time for a new prescription.** *J Clin Oncol* 2014;32(36):4027-8.
- Shih YC et al. **Delivering high-quality and affordable care throughout the cancer care continuum.** *J Clin Oncol* 2013;31(32):4151-7.
- Sledge GW Jr et al. **CancerLinQ and the future of cancer care.** *Am Soc Clin Oncol Educ Book* 2013:430-4.
- Smith TJ et al. **What makes the last few months of treatment so expensive?** *Proc ECCO* 2013;Abstract 190.
- Sprandio JD et al. **Data-driven transformation to an oncology patient-centered medical home.** *J Oncol Pract* 2013;9(3):130-2.
- Towle EL et al. **The National Practice Benchmark for Oncology, 2014 report on 2013 data.** *J Oncol Pract* 2015;11(1):385-406.
- Zimmermann C et al. **Early palliative care for patients with advanced cancer: A cluster-randomised controlled trial.** *Lancet* 2014;383(9930):1721-30.